290 related articles for article (PubMed ID: 33983906)
21. Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia.
Richmond J; Carol H; Evans K; High L; Mendomo A; Robbins A; Meyer C; Venn NC; Marschalek R; Henderson M; Sutton R; Kurmasheva RT; Kees UR; Houghton PJ; Smith MA; Lock RB
Clin Cancer Res; 2015 Mar; 21(6):1395-405. PubMed ID: 25573381
[TBL] [Abstract][Full Text] [Related]
22. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
23. SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
Bu J; Chen A; Yan X; He F; Dong Y; Zhou Y; He J; Zhan D; Lin P; Hayashi Y; Sun Y; Zhang Y; Xiao Z; Grimes HL; Wang QF; Huang G
Leukemia; 2018 Apr; 32(4):890-899. PubMed ID: 29249820
[TBL] [Abstract][Full Text] [Related]
24. Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.
Fidyt K; Pastorczak A; Goral A; Szczygiel K; Fendler W; Muchowicz A; Bartlomiejczyk MA; Madzio J; Cyran J; Graczyk-Jarzynka A; Jansen E; Patkowska E; Lech-Maranda E; Pal D; Blair H; Burdzinska A; Pedzisz P; Glodkowska-Mrowka E; Demkow U; Gawle-Krawczyk K; Matysiak M; Winiarska M; Juszczynski P; Mlynarski W; Heidenreich O; Golab J; Firczuk M
Mol Oncol; 2019 May; 13(5):1180-1195. PubMed ID: 30861284
[TBL] [Abstract][Full Text] [Related]
25. Fms-like tyrosine kinase 3 ligand stimulation induces MLL-rearranged leukemia cells into quiescence resistant to antileukemic agents.
Furuichi Y; Goi K; Inukai T; Sato H; Nemoto A; Takahashi K; Akahane K; Hirose K; Honna H; Kuroda I; Zhang X; Kagami K; Hayashi Y; Harigaya K; Nakazawa S; Sugita K
Cancer Res; 2007 Oct; 67(20):9852-61. PubMed ID: 17942916
[TBL] [Abstract][Full Text] [Related]
26. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
27. Functional interrogation of HOXA9 regulome in MLLr leukemia via reporter-based CRISPR/Cas9 screen.
Zhang H; Zhang Y; Zhou X; Wright S; Hyle J; Zhao L; An J; Zhao X; Shao Y; Xu B; Lee HM; Chen T; Zhou Y; Chen X; Lu R; Li C
Elife; 2020 Oct; 9():. PubMed ID: 33001025
[TBL] [Abstract][Full Text] [Related]
28. Glycoproteome remodeling in MLL-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract][Full Text] [Related]
29. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
[TBL] [Abstract][Full Text] [Related]
30. CN470 is a BET/CBP/p300 multi-bromodomain inhibitor and has an anti-tumor activity against MLL-rearranged acute lymphoblastic leukemia.
Imayoshi N; Yoshioka M; Tanaka K; Yang SM; Akahane K; Toda Y; Hosogi S; Inukai T; Okada S; Maloney DJ; Nakahata T; Takita J; Kato I; Ashihara E
Biochem Biophys Res Commun; 2022 Jan; 590():49-54. PubMed ID: 34971957
[TBL] [Abstract][Full Text] [Related]
31. Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings.
Urtishak KA; Robinson BW; Rappaport EF; Sarezky MD; Biegel JA; Nichols KE; Wilmoth DM; Wang LS; Stern JW; Felix CA
Pediatr Blood Cancer; 2016 Jul; 63(7):1175-80. PubMed ID: 26999444
[TBL] [Abstract][Full Text] [Related]
32. The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential.
Wong SH; Goode DL; Iwasaki M; Wei MC; Kuo HP; Zhu L; Schneidawind D; Duque-Afonso J; Weng Z; Cleary ML
Cancer Cell; 2015 Aug; 28(2):198-209. PubMed ID: 26190263
[TBL] [Abstract][Full Text] [Related]
33. Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia.
Schotte D; Lange-Turenhout EA; Stumpel DJ; Stam RW; Buijs-Gladdines JG; Meijerink JP; Pieters R; Den Boer ML
Haematologica; 2010 Oct; 95(10):1675-82. PubMed ID: 20494936
[TBL] [Abstract][Full Text] [Related]
34. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
35. Uncovering NOTCH1 as a Promising Target in the Treatment of
Fischer J; Erkner E; Fitzel R; Radszuweit P; Keppeler H; Korkmaz F; Roti G; Lengerke C; Schneidawind D; Schneidawind C
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833915
[No Abstract] [Full Text] [Related]
36. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
37. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
38. Covert preleukemia driven by MLL gene fusion.
Zuna J; Burjanivova T; Mejstrikova E; Zemanova Z; Muzikova K; Meyer C; Horsley SW; Kearney L; Colman S; Ptoszkova H; Marschalek R; Hrusak O; Stary J; Greaves M; Trka J
Genes Chromosomes Cancer; 2009 Jan; 48(1):98-107. PubMed ID: 18932267
[TBL] [Abstract][Full Text] [Related]
39. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
40. A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
Jassinskaja M; Ghosh S; Watral J; Davoudi M; Claesson Stern M; Daher U; Eldeeb M; Zhang Q; Bryder D; Hansson J
Leukemia; 2024 May; 38(5):1115-1130. PubMed ID: 38555405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
